title: Prevention of infection in acute leukemia.
abstract: In a randomized study comparing cotrimoxazole plus colistin with ciprofloxacin, each in combination with nonabsorbable antimycotics, the incidence of major infections in terms of septicemias and pneumonias as well as of minor infections and episodes of unexplained fever (FUO) was higher in patients treated with ciprofloxacin. In cases of microbiologically documented infections, gram-positive cocci dominated by far. In surveillance cultures of oral washings and of feces, gram-negative enterobacteria were only rarely detected; however, large numbers of cultures were positive for Acinetobacter species. There were four cases of documented Pneumocystis carinii pneumonia in patients not receiving cotrimoxazole. The incidence of documented mycotic infections as well as the detection of fungi in surveillance cultures was similar in both treatment groups. A decrease in the number of adverse events, especially of allergic reactions, could not be achieved by the administration of ciprofloxacin. In conclusion, cotrimoxazole plus colistin in combination with nonabsorbable antimycotics remains the standard regimen for prevention of infection in patients with acute leukemia undergoing aggressive remission induction therapy. A detailed analysis of study II will be prepared for publication.
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.forename: S
authors.initials: S
authors.lastname: Daenen
authors.forename: B E
authors.initials: BE
authors.lastname: de Pauw
authors.forename: H G
authors.initials: HG
authors.lastname: de Vries-Hospers
authors.forename: A W
authors.initials: AW
authors.lastname: Dekker
authors.forename: J P
authors.initials: JP
authors.lastname: Donnelly
authors.forename: W
authors.initials: W
authors.lastname: Gaus
authors.forename: E
authors.initials: E
authors.lastname: Haralambie
authors.forename: W
authors.initials: W
authors.lastname: Kern
authors.forename: H
authors.initials: H
authors.lastname: Konrad
mesh_terms: D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000209:etiology; D007938:Leukemia / Q000150:complications* / Q000628:therapy; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000150:complications; D009643:Norfloxacin / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D009643:Norfloxacin; D003091:Colistin